The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

Jose R Arribas, Andrzej Horban, Jan Gerstoft, Gerdt Fätkenheuer, Mark Jason Nelson, Nathan Clumeck, Federico Pulido, Andrew Hill, Yvon van Delft, Thomas Stark, Christiane Moecklinghoff

    177 Citations (Scopus)

    Abstract

    In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.
    Original languageEnglish
    JournalAIDS
    Volume24
    Issue number2
    Pages (from-to)223-30
    Number of pages8
    DOIs
    Publication statusPublished - 16 Jan 2010

    Fingerprint

    Dive into the research topics of 'The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml'. Together they form a unique fingerprint.

    Cite this